RxDoctor Payments Data

Ainsley Rusevlyan, DPM

Podiatrist · Washington, NCNPI 1851518393

Payments from drug & device makers

$716in general payments, 2019–2025

Across 14 payments — averaging $51.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Paratek Pharmaceuticals, Inc.$142
  • Heron Therapeutics, Inc.$125
  • Amgen$124
  • Treace Medical Concepts, Inc.$113
  • Medtronic$104
  • Stability Biologics, LLC$70
  • plus $39 from 2 others

What the payments were for

  • Consulting fees$7010%
  • Food & beverage$64790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$716 in reported general payments places this provider in the 30th percentile of 109 podiatrist providers in North Carolina.

See all podiatrist providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,699,937
Medicare patients
658
Services billed
3,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LyricaPregabalin13$14,735
Duloxetine Hcl245$4,321
Gabapentin373$2,965
Pregabalin170$2,746
Ketoconazole78$1,443
Nitro-BidNitroglycerin17$1,199
Diclofenac Sodium26$1,079
Celecoxib103$1,071
Ciclopirox28$840
Cephalexin203$832
Imiquimod24$716
Nitroglycerin PatchNitroglycerin28$540
Colchicine38$522
Doxycycline Hyclate51$319
Terbinafine Hcl51$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerLyrica$24$14,73513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 109 podiatrist providers in North Carolina.

Other podiatrist in Washington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →